Position in NVS
as of Mar 31, 2026
· filed May 19, 2026
Position Value
$4,735
-$10,270 QoQ
Shares Held
31
-75.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Silicon Valley Capital Partners holds $14,966,250 across 12 Drug Manufacturers - General names. NVS ranks #9 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
13,009 | $11,965,287 | |
| 2 | JNJ |
Johnson & Johnson
|
9,659 | $2,361,045 | |
| 3 | PFE |
Pfizer Inc
|
7,397 | $207,707 | |
| 4 | AMGN |
Amgen Inc
|
487 | $171,350 | |
| 5 | ABBV |
AbbVie Inc.
|
580 | $126,144 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
1,154 | $69,990 | |
| 7 | MRK |
Merck & Co., Inc.
|
380 | $45,710 | |
| 8 | NVO |
Novo Nordisk A S
|
276 | $10,143 |
All Filings in NVS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,735 | 31 | Shares | Sole | 2026-05-19 | |
| 2025-06-30 | $15,005 | 124 | Shares | Sole | 2025-09-11 | |
| 2025-03-31 | $28,538 | 256 | Shares | Sole | 2025-05-28 | |
| 2024-12-31 | $24,911 | 256 | Shares | Sole | 2025-01-29 | |
| 2024-09-30 | $29,445 | 256 | Shares | Sole | 2024-10-30 | |
| 2024-06-30 | $27,253 | 256 | Shares | Sole | 2024-10-30 | |
| 2024-03-31 | $24,182 | 250 | Shares | Sole | 2024-04-29 | |
| 2023-12-31 | $25,242 | 250 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $25,465 | 250 | Shares | Sole | 2023-11-06 | |
| 2023-06-30 | $25,227 | 250 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||